GlaukosCorp

Glaukos is an ophthalmic medicines and medical technology company focused on developing treatments for glaucoma, corneal disorders, and retinal diseases. Its mission is to advance the standard of care through pharmaceutical innovation, device engineering, and procedural expertise. A pioneer of micro-invasive glaucoma surgery, Glaukos reports that its products have treated more than 3.5 million eyes and that it operates commercially in over 20 countries.

The company offers a portfolio of glaucoma therapies, including iDose TR, iStent infinite, iStent inject W, iAccess, and Mitosol. For corneal disease, Glaukos provides Epioxa and cross-linking interventions intended to slow or halt progressive keratoconus and help preserve vision. In retina, it is developing sustained-release drug-delivery platforms for retinal diseases. Glaukos also supports clinicians with product information, clinical evidence, procedural resources, physician presentations, and reimbursement materials. Beyond its therapies, the company highlights research and development, patient support, philanthropy, and global outreach aimed at expanding access to vision care. Its work spans the development of new treatments and practical resources for healthcare professionals and patients.